数据提取表模板.docxVIP

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsSourceStudy ID (Author/year): Contact details: EligibilityConfirm eligibility for review:Reason for exclusion:MethodsStudy design (multicenter/randomized/single or double blinding/parallel or crossover or factorial):Presence of randomization (yes or no): Appropriate method of randomization:Presence of double blinding:Appropriate method of double blinding:Description of withdrawals and dropouts:Jadad Score (1-5):ERASUREParticipantsCountry:Race:Date of study:Total number: Mean age (or middle age):BMI(proportion):Age range: 18 years of age or olderMale (proportion):69.0%Female (proportion):31.0%Dropout (%):0Baseline (week 0) visit:Body surface area(BSA) ,mean: PGA: PASI (mean):Time since psoriasis diagnosis (mean):Number(proportion) of having history of psoriatic arthritis %:Previous systemic treatment:Any (%):Conventional agent (%):Biologic agent (%):TNF inhibitor (%):Anti?interleukin-12 and anti–interleukin-23 agent(%):No response to previous use of TNF inhibitor (%):Interventions (characteristics of exercise type / frequency /duration /intensity)Experimental group (number + intervention):Control group (number + intervention):No of times/week:No of weeks:Duration (wk):Outcomes 1.PGA 0/1experimental group:PGA at baseline: the proportionof patients achieving PGA 0/1 at week12:The median time to achieve a PGA 0/1: control group 1:PGA at baseline: the proportionof patients achieving PGA 0/1 at week12: The median time to achieve a PGA 0/1:tcontrol group 2:PGA at baseline: the proportionof patients achieving PGA 0/1 at week12: The median time to achieve a PGA 0/1:the overall groups:PGA at baseline:2.PASIexperimental group:PASI at baseline (mean±SD):the proportion of patients achieving PASI 75 response at week 12: the proportion of patients achieving PASI 90 response at week 12: the proportion of patients achieving PASI 100 response at week 12:The median time to achieve a PASI 75: control group 1:PASI at baselin